These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 36119464)

  • 1. PD-1 inhibitor therapy causes multisystem immune adverse reactions: a case report and literature review.
    Yin N; Liu X; Ye X; Song W; Lu J; Chen X
    Front Oncol; 2022; 12():961266. PubMed ID: 36119464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events.
    Poto R; Troiani T; Criscuolo G; Marone G; Ciardiello F; Tocchetti CG; Varricchi G
    Front Immunol; 2022; 13():804597. PubMed ID: 35432346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
    Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
    Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoimmune complications of immunotherapy: pathophysiology and management.
    Chan KK; Bass AR
    BMJ; 2020 Apr; 369():m736. PubMed ID: 32253223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
    Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
    Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune-related adverse events in various organs caused by immune checkpoint inhibitors.
    Okiyama N; Tanaka R
    Allergol Int; 2022 Apr; 71(2):169-178. PubMed ID: 35101349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
    Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
    World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.
    Song P; Zhang D; Cui X; Zhang L
    Thorac Cancer; 2020 Sep; 11(9):2406-2430. PubMed ID: 32643323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer.
    Li N; Wang G; Hou X; Tai R; Huang S; He Z; Lei L; Xu S; Yang S
    Int Immunopharmacol; 2022 Jul; 108():108803. PubMed ID: 35569432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
    Kotwal A; Kottschade L; Ryder M
    Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
    [No Abstract]   [Full Text] [Related]  

  • 12. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
    Michot JM; Lazarovici J; Tieu A; Champiat S; Voisin AL; Ebbo M; Godeau B; Michel M; Ribrag V; Lambotte O
    Eur J Cancer; 2019 Nov; 122():72-90. PubMed ID: 31634647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events.
    Nakamura Y
    Front Med (Lausanne); 2019; 6():119. PubMed ID: 31192215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors.
    Yao L; Jia G; Lu L; Bao Y; Ma W
    Int Immunopharmacol; 2020 Aug; 85():106628. PubMed ID: 32474388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
    Bhardwaj M; Chiu MN; Pilkhwal Sah S
    Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
    Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
    BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
    Gu YC; Liu Y; Xie C; Cao BS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy-associated cardiovascular toxicities: insights from preclinical and clinical studies.
    Kong Y; Wang X; Qie R
    Front Oncol; 2024; 14():1347140. PubMed ID: 38482205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article.
    Chen CH; Yu HS; Yu S
    Curr Oncol; 2022 Apr; 29(4):2871-2886. PubMed ID: 35448208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies.
    Yang W; Lei C; Song S; Jing W; Jin C; Gong S; Tian H; Guo T
    Cancer Cell Int; 2021 Nov; 21(1):589. PubMed ID: 34727927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.